STARC: Difference between revisions
Jump to navigation
Jump to search
(Redirecting 'STARC' to 'Angioplasty/Atherectomy/Laser Therapy: Trapidil (Triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results Of The Randomized, Double-Blin) |
No edit summary |
||
Line 1: | Line 1: | ||
#REDIRECT [[Angioplasty/Atherectomy/Laser Therapy: Trapidil (Triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results Of The Randomized, Double-Blind Starc Study]] | #REDIRECT [[Angioplasty/Atherectomy/Laser Therapy: Trapidil (Triazolopyrimidine), A Platelet-Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results Of The Randomized, Double-Blind Starc Study]] | ||
[[Category:Clinical trials]] |